Latest Healthcare News

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.

Memphasys has locked in a 12-month exclusive supply agreement with Monash IVF for its Felix™ sperm selection system, marking its biggest commercial contract to date and setting a foundation for recurring revenue.

InteliCare (ASX:ICR) is hitting a commercial inflection point, backed by a landmark $8.8 million contract with mecwacare and a growing pipeline across aged care sectors. Its AI-powered platform promises measurable improvements in care outcomes and operational efficiency.

Paradigm Biopharmaceuticals has completed enrolment ahead of schedule in its pivotal Phase 3 trial for Zilosul®, enrolling 538 patients with knee osteoarthritis and maintaining its timeline for interim and final results.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

Echo IQ has partnered with Mayo Clinic to assess its AI platform's ability to predict heart failure risk in patients undergoing cancer therapy, targeting the growing cardio-oncology sector.

Monash IVF lowers its FY26 underlying NPAT guidance to $17-18 million, citing a 4.7% drop in Australian stimulated IVF cycles. Despite this, the company has expanded its national market share to 20.1% and seen international volume growth.

TruScreen has secured clinical validation from the world’s largest cervical screening study in China, setting the stage for rapid market expansion across Asia, Africa, and Europe.

Green Cross Health Limited reported a 28% rise in net profit to NZD 20.4 million for FY26, driven by gains in both pharmacy and medical divisions. The company announced a conditional sale of its Medical division to Tend Health for NZD 270 million, aiming to refocus on its core pharmacy business.